Title: NGAL is a Precocious Marker of Therapeutic Response
Volume: 17
Issue: 8
Author(s): Valeria Cernaro, Davide Bolignano, Valentina Donato, Antonio Lacquaniti, Antoine Buemi, Eleonora Crascì, Silvia Lucisano and Michele Buemi
Affiliation:
Keywords:
NGAL, acute renal failure, chronic kidney disease, clinical nephrology, clinical pharmacology, glomerulonephritis, vasculitis, antimicrobial, gentamicin, microalbuminuria, Crohn's disease, flogistic, Infliximab, idiopathic, streptozotocin, angiotensin, sepsis, inefficacy, etiologic, immunosuppressors
Abstract: NGAL (Neutrophil Gelatinase-Associated Lipocalin) is a small 25-kD peptide belonging to the lipocalin superfamily. Several studies highlight its role as an organ injury and disease activity biomarker. In the present review, instead, we wanted to study NGAL as a precocious marker of therapeutic response in renal and non-renal diseases (glomerulonephritis, vasculitis, LES, Crohns disease and other chronic inflammatory pathologies). The obtained outcomes support the hypothesis that NGAL could be employed as a biomarker of response to different therapeutic schemes, because its levels sensibly and precociously change compared to other haematologic and biochemical parameters.